FMP
AMEX
0.34 USD
0.0025 (0.73%)
Mr. John Koconis M.B.A.
Healthcare
Biotechnology
https://www.timberpharma.com
AMEX
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in...
0001504167
US8870802084
887080109
110 Allen Road
973 314 9577
US
9
Sep 8, 2014
0001504167
AMEX
Biotechnology
Healthcare
887080109
US8870802084
US
0.34
-0.65
107.9k
1.18M
-
0.32-3.39
2.53
-
-
-
-
-0.17
-
https://www.timberpharma.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.